Abstract
Human laboratory studies have a rich history in the alcoholism field and several important determinants of alcohol use disorders have been successfully modeled under controlled laboratory conditions. Laboratory paradigms have been employed to identify biobehavioral risk markers for alcohol misuse and more recently, have been integrated with behavioral genetic, neuroimaging, and pharmacological approaches to further elucidate the neuropathophysiology of addiction and to screen for efficacious treatments. This review will address the rationale and application of human laboratory models to advance pharmacotherapy development for alcohol dependence. It is argued that when properly implemented, laboratory models may help scientists and clinicians understand mechanisms of pharmacotherapy response, which in turn may inform efforts to optimize the currently available and newly developed treatments for alcoholism. Limitations and future directions are discussed.
Keywords: Alcohol, laboratory studies, craving, pharmacotherapy, genetics
Current Pharmaceutical Design
Title: Application of Human Laboratory Models to Pharmacotherapy Development for Alcohol Dependence
Volume: 16 Issue: 19
Author(s): Lara A. Ray, Kent E. Hutchison and Molly Tartter
Affiliation:
Keywords: Alcohol, laboratory studies, craving, pharmacotherapy, genetics
Abstract: Human laboratory studies have a rich history in the alcoholism field and several important determinants of alcohol use disorders have been successfully modeled under controlled laboratory conditions. Laboratory paradigms have been employed to identify biobehavioral risk markers for alcohol misuse and more recently, have been integrated with behavioral genetic, neuroimaging, and pharmacological approaches to further elucidate the neuropathophysiology of addiction and to screen for efficacious treatments. This review will address the rationale and application of human laboratory models to advance pharmacotherapy development for alcohol dependence. It is argued that when properly implemented, laboratory models may help scientists and clinicians understand mechanisms of pharmacotherapy response, which in turn may inform efforts to optimize the currently available and newly developed treatments for alcoholism. Limitations and future directions are discussed.
Export Options
About this article
Cite this article as:
A. Ray Lara, E. Hutchison Kent and Tartter Molly, Application of Human Laboratory Models to Pharmacotherapy Development for Alcohol Dependence, Current Pharmaceutical Design 2010; 16 (19) . https://dx.doi.org/10.2174/138161210791516422
DOI https://dx.doi.org/10.2174/138161210791516422 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticholinesterase and Pharmacokinetic Profile of Phenserine in Healthy Elderly Human Subjects
Current Alzheimer Research [General Articles] Cannabinoids: Mechanisms and Therapeutic Applications in the CNS
Current Medicinal Chemistry Stem Cell Therapy: A Promising Approach in Treatment of COVID-19
Current Stem Cell Research & Therapy mTOR Inhibitors in Tuberous Sclerosis Complex
Current Neuropharmacology Gastrodia Elata Bl Attenuates Methamphetamine-Induced Dopaminergic Toxicity Via Inhibiting Oxidative Burdens
Current Neuropharmacology Use of Natural Antimicrobials from a Food Safety Perspective for Control of Staphylococcus aureus
Current Pharmaceutical Biotechnology Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Impact of Opioid Receptor, Mu 1 (OPRM1) Polymorphisms on Pain Sensitivity and Clinical Response to Opioid Analgesic Therapy
Current Pharmacogenomics and Personalized Medicine Novel Therapeutic Targets for the Treatment of Depression
Current Medicinal Chemistry - Central Nervous System Agents REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets Energy Metabolism Impairment in Migraine
Current Medicinal Chemistry Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option
Current Topics in Medicinal Chemistry Preclinical Data Supporting/Refuting the Use of Hypericum perforatum in the Treatment of Depression
CNS & Neurological Disorders - Drug Targets Chronic Kidney Disease and Sleeping Disordered Breathing (SDB)
Current Hypertension Reviews Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Rivastigmine for Refractory REM Behavior Disorder in Mild Cognitive Impairment
Current Alzheimer Research Editorial: Conceptualizing Adolescent Problems in Dimensional Terms
Adolescent Psychiatry Early Age of Migraine Onset is Independently Related to Cognitive Decline and Symptoms of Depression Affect Quality of Life
Current Neurovascular Research The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation
Current Alzheimer Research